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ABSTRACT 
Objectives: This study was aimed to determine (1) the associations between adherence to warfarin, social support, perception of illness, 
and demographic factors on the quality of international normalized ratios (INRs); as well as (2) the relationship between the patients’ 
scores in the Malaysian medication adherence scale (MALMAS) and their current INRs. 
Method: This cross-sectional survey was conducted from November 2017 to January 2018 at the warfarin clinic of Jerantut Hospital, 
Malaysia. 
Results: Some 58 participants were recruited, of whom 70.7% were diagnosed with atrial fibrillation (AF). Overall, 87.9% of the 
participants claimed adherence to their warfarin regimens. Patients with good-quality INR therapy were significantly older, had a 
higher median income and longer appointment durations. In terms of illness perception (IP), participants with good-quality INR therapy 
had significantly lower scores in the identity, personal control, and consequence domains. Overall, the total scores for IP were 
significantly lower in the good-quality INR therapy. Meanwhile, the MALMAS scores were significantly lower in patients with sub-
therapeutic current INR. However, there were no associations between warfarin adherence and perceived social support with current 
TTR. 
Conclusion: Monitoring of demographic factors and IP’s domains is vital since they were associated with quality of INR therapy. 
Meanwhile, the occurrence of sub-therapeutic current INR should raise suspicion of poor adherence in these patients. Overall, IP and 
MALMAS are useful tools that should be integrated into the patient care protocols. 
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INTRODUCTION 
Today, pharmacists have become actively involved in patient 
monitoring and warfarin-prescribing [1]. Warfarin is used in the 
treatment of various thromboembolism-related disorders [2] 
but owing to its narrow therapeutic index, regular international 
normalized ratio (INR) monitoring is required. This is vital for (1) 
patients’ safety in term of preventing complications like minor-
to-severe bleeding in light of over-anticoagulation [2], and (2) 
ensuring treatment efficacy by avoiding sub-therapeutic INR 
due to insufficient dosing[2]. 
 
In the current settings, physicians and pharmacists usually 
prescribe clinical follow-ups ranging from three days (in 
unstable patients) to three months (in stable patients) and dose 
adjustments are made based on a normogram provided by the 
Malaysian Ministry of Health [3]. 
 
The duration of warfarin treatment ranges from a few months 
to lifelong [2] and healthcare practitioners are aware that the 
achievement of prolonged time in therapeutic range (TTR) is a 
key objective of the treatment [2]. Hence, a good motivation 
and long-term commitment from both patients and caregivers 
in terms of adherence to follow-ups and lifestyle changes such 
as diet restriction as well as warfarin intake is needed [4]. 
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While the associations between social support and TTR have 
rarely been explored, yet variations in relationships between 
warfarin adherence(4,5,15) and illness-perception (IP)(6,26)  
with TTR have been reported in different studies making their 
findings difficult to be generalized for clinical practices. Thus in 
current study, we aimed to determine the relationships 
between adherence to warfarin with TTR and current 
international normalized ratio (INR) and also the relationships 
between social support and IP on TTR.  
 
METHOD 
This cross-sectional survey was conducted at the warfarin clinic 
of Jerantut Hospital, Malaysia from November to December 
2017. It was approved by the Medical Research and Ethics 
Committee (MREC) (registration number: NMRR-17-2036-
37528). Convenience sampling was performed, and written 
consent was obtained from the potential respondents prior to 
the survey. Participants who were at least 18 years of age, able 
to give consent, and on warfarin for at least six months were 
recruited. Those who refused to participate, or had language 
barriers, speech/ hearing disabilities, mental disorders, and 
histories of defaulting treatment were excluded. The 
researchers spent between 20 and 30 minutes to conduct the 
survey on each patient during warfarin clinic days.  
 
In the pilot study, the Malay-version Malaysian Medication 
Adherence Scale (MALMAS) [7] scores of 30 adherent (TTR > 
60%) and non-adherent (TTR < 60%) patients were normally 
distributed with a standard deviation of 0.8. Meanwhile, the 
true difference between both groups’ means was 0.5. With 
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reference to this, 41 subjects were needed for the adherent and 
non-adherent groups respectively to achieve a study power of 
80%. Also, the Type I error in this test was set at 0.05. 
 
MALMAS [7], Multidimensional Scale of Perceived Social 
Support (MSPSS-M) [8], and illness perception (IP) [9] 
questionnaires were used to assess warfarin adherence, social 
support, and IP respectively. Demographic data was obtained 
verbally from the patients, while six-to-twelve-month INR 
histories were extracted from participants’ INR booklets. 
 
MALMAS consisted of eight questions. The first item of the 
MALMAS contained five possible responses: (1) all the time, (2) 
often, (3) sometimes, (4) rarely, and (5) never. The remaining 
seven items had dichotomous yes-no responses options. Items 
two to four and six to eight were reverse coded (i.e. "no" = 1, 
"yes" = 0), while the converse was true for item five ("no" = 0, 
"yes" = 1). The first item had five negatively scored response 
options that ranged from zero (all the time) to one (never). The 
total MALMAS score, which ranged from 0 to 8, was used to 
assess the patients’ medication adherence one month prior to 
the administration of the questionnaire [7]. Patients whose 
scores were less than six were categorized as non-adherent. 
 
MSPSS-M comprised of 12 questions whose scores ranged from 
one to seven marks each. Hence, the total mark ranged from 
seven to 84. Questions 1, 2, and 10 evaluated the patients' 
perceptions of support from their significant others, questions 
3, 4, 8, and 11 family members, and questions 6, 7, 9, and 12 
friends [8,10]. Higher score reflected better social support.  
  
The Malay version of IP was validated on the hypertensive 
population in Malaysia, and the Cronbach’s alpha was found to 
be 0.65. This questionnaire consisted of eight questions, each 
of which was scored between zero and ten. Ergo, this 
questionnaire had a maximum total mark of 80. The questions 
on personal control (question 3), treatment control (question 
4), and understanding of illness (question 7) were reverse-
scored, whereby lower scores indicated a less negative view of 
the illness. Conversely, higher overall scores indicated more 
negative view of the illness [9]. Time in therapeutic range (TTR) 
was measured using the Rosendaal formula [11, 12], whereby 
participants who had a TTR of > 60% were considered to have 
achieved good quality INR control [13,14,29,30]. 
 
Statistical analyses were performed using the Statistical 
Package for Social Sciences (SPSS) version 18.0 software. Chi-
square test was employed to analyze the categorical variables 
and T-test or Mann Whitney U test was used to determine the 
relationships between the categorical and numerical variables. 
The outcomes of the continuous variables were expressed as 
means ± standard deviations (SDs), or medians and 
interquartile ranges (IQRs) where applicable. A P-value of < 0.05 
was considered to be statistically significant. 
 
 
RESULTS 
Participants’ characteristics 
As of December 2017, 75 patients have attended the warfarin 
clinic at Jerantut Hospital, all of whom were approached to 
solicit their participation in the survey. However, nine were 
excluded owing to language barriers, six on treatment for less 
than six months, and two with histories of defaulting treatment 
in the past year. The remaining 58 patients agreed to 
participate in the survey, hence giving a power of 65%.  
 
In the current survey, 48.3% (n = 28) of the participants were 
males, and the median age was 63.5 years (IQR: 16.3). The 
majority of the respondents (70.7%; n = 41) were diagnosed 
with atrial fibrillation (AF) and received warfarin for a median 
of 41.5 months (IQR: 80.0). For the past six to 12 months, the 
median follow-up interval was once every 27 days (IQR: 19) and 
the mean warfarin daily dose of 2.5 ± 1.2 mg per day. 
 
Overall, 87.9% (n = 51) of the participants claimed adherence to 
their warfarin regimens. For IP, participants scored the highest 
in the timeline- (median: 9; IQR: 4.3) and illness-specific 
(median: 9; IQR: 2) domains. Overall, mean total IP score was 
35.1 ± 8.1. As for social support, the median scores for spousal- 
and friend-support were both 20 (IQR: 9 and 5 respectively). 
The mean scores for family support and total social support 
were 23.7 ± 3.6 and 65.3 ± 11.3 respectively. These data are 
presented in Table 1.                    
         
Characteristic differences between patients with good and 
poor quality INR control 
In terms of demographic factors, it was noted that patients with 
good quality INR control were older (median age: 68 years; IQR: 
18) than their poor quality INR control counterparts (median 
age: 50 years; IQR: 22) (P = 0.013). The former group also 
recorded a higher median income (Malaysian Ringgit/ MYR 1 
000; IQR: 1300) vis-a-vis the latter group (MYR 300; IQR: 1310). 
Patients with good INR control were under longer follow-up 
intervals (median: 42 days; (IQR: 20) than poor quality INR 
controlones (median: 24 days; IQR: 6) (P = 0.001). However, 
duration on warfarin treatment and daily warfarin dose had no 
significant association with INR control.  Good INR control 
group had lower scores in the following domains: identity 
(median: 3.0 vs 4.5; IQR: 5.5 vs 4.0; P = 0.039), personal control 
(median: 2.0 vs 3.0; IQR: 2.0 vs 2.0; P = 0.047), consequences 
(median: 1.5 vs 3.0; IQR: 3.0 vs 4.8; P = 0.016). Likewise, the 
total IP score was significantly lower in patients with good INR 
control (median: 32.1; IQR: 7.5) as compared to those with poor 
INR control (median: 37.5; IQR: 8.0) (P = 0.012). Other IP and 
perceived social support domains did not have a significant 
influence on INR control (Table 2).        
        
Relationship between MALMAS and current INR readings 
As shown in Figure 1, patients who managed to maintain the 
target INR for the past four to six weeks had significantly higher 
MALMAS scores (median: 8.0; IQR: 1.0) than their counterparts 
who failed to do so (median: 7.0; IQR: 2.0) (P = 0.022). 
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DISCUSSION 
In addition to the relationship between MALMAS scores and 
current INR readings, this was the first study that investigated 
the associations between medication adherence, social 
support, and illness perception with INR control. 
 
Roles of TTR  
TTR lower than 60% increased risks of bleeding [12,13] yet its 
associations with stroke and systemic embolism varied 
between different studies[12,13,14]. A study between 
subgroups of patients with TTRs of 60 to 75% versus those that 
exceeded 75% found that the risks of major bleeding, mortality, 
and stroke were not significantly different between the two 
groups [14]. Thus the choice of using the TTR value of 60% and 
above as an indication of good quality INR therapy [29,30]. 
 
Associations between demographic factors and warfarin 
therapy on TTR  
Our findings supported the associations between advanced age 
and higher income on quality of INR therapy [17,18]. The 
importance of good quality INR therapy in lower-income 
patients should not be underestimated since the failure to 
achieve the same will ultimately results in higher risks of 
haemorrhage and death [19]. 
 
Predictably, those with poor quality INR control had 
significantly shorter follow-up intervals (i.e. time between 
follow-up sessions) as compared to patients with good quality 
INR control. In this study, patients who achieved good quality 
INR had their appointments once every 42 days, which was 
much longer than that of their overseas counterparts (21 – 24 
days) [20]. On the contrary, patients with lower TTRs had their 
appointments scheduled more frequently, i.e. once in every 
three weeks or so. Hence, this could be an indication that 
shorter follow-up intervals should be considered in patients 
with poor quality INR in current setting.  
 
Adherence 
Multiple tools have been used to determine warfarin 
adherence such as pill counts, medication event monitoring 
systems (MEMS), and self-reported questionnaires 
[4,5,12,15,21,22]. Nonetheless, self-reported adherences 
varied between studies depending on the assessment tools 
used [4,5,12,15,22]. A frequently-utilized questionnaire for the 
evaluation of medication adherence is the eight-item modified 
Morisky medication adherence scale (MMAS-8) [4,5,12]. From 
there, a new questionnaire has been developed by Malaysian 
researchers, and it was named “Malaysian medication 
adherence scale” (MALMAS) [7]. 
 
Adherence and TTR 
Despite the high adherence to warfarin (about 88%) in this 
study, only around 45% of the patients achieved good quality 
INR control. Nonetheless, this figure was still slightly higher 
than the 15% to 35% in other studies [4,5]. It should be noted 
that comparisons are difficult since those studies have used 
higher cut-off points of 70% and 75% for defining therapeutic 
TTR [4,5]. Also, lack of clear correlation between self-reported 
adherence and TTR is not uncommon probably due to different 
TTR calculations and therapeutic TTR definitions [4,5,15]. 
 
Even though a recent study has reported that warfarin 
adherence was related to TTR [5] yet other research have found 
that only 26% to 35% of patients managed to achieve a  TTR of 
more than 75% despite the presence of self-reported 
adherence levels of up to 46% to 48% [4,15]. Nevertheless, this 
observation was not unexpected owing to the fact that MMAS-
8 had limited recall period of two weeks only [4]. This was 
supported by our finding that higher MALMAS scores were only 
predictive of current INR readings but not TTR. Likewise, 
previous studies have shown that adherence measurement 
tools like the visual analogue scale (VAS) and 7-day recall test 
were more predictive of short-term INR changes [22].Other tool 
such as MEMS have revealed that good adherence within the 
past 12 months was associated with good TTR [23] yet this 
device is far too costly to be routinely used in daily clinical 
practice [21]. Based on this finding, monitoring of adherence 
should essentially comprised the administration of self-
reported questionnaires such as MALMAS at every visit, along 
with an emphasis on warfarin adherence in patients with poor 
quality INR control. 
  
Social support and TTR  
In hypertensive patients, medication-adherence counselling 
and treatment optimization by pharmacists have led to 
improvements in social support and blood pressure. 
Nevertheless, the effect of social support on blood pressure 
was insignificant [24]. 
 
Based on a previous study [24], it was expected that social 
support did not markedly differ between the poor and good 
quality INR control groups. This was due to the fact that the 
participants of this research were managed (in terms of 
warfarin dosing, warfarin adherence, and lifestyle modification 
counselling) by trained pharmacists at every visit. This indicates 
that one of the most important outcomes of social support is to 
retain patients within the care system and hence, avoid 
complications that are attributable to their illnesses [25]. 
 
IP and TTR 
 IP has been explored in warfarin-taking patients prior to 
switching treatment to novel oral anticoagulants (NOACs)[6] as 
well as its changes upon receiving educational interventions 
[26].  
 
It was reported that IP did not predict TTR changes among 
 46 and 51 participants whom underwent educational 
interventions and the usual care respectively [26]. However, 
this could be attributed to the fact that IP was only assessed in 
27 participants. On the contrary, a study on 148 AF or venous 
thromboembolism (VTE) has found that the scores for the 
consequence and timeline (cyclical) domains were significantly 
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higher in patients whose TTRs were less than 50% as compared 
to those whose TTRs exceeded 75% [6]. Meanwhile timeline 
(acute chronic) and illness coherence domains scores were 
significantly lower in the former group relative to the latter 
group [6]. Evidently, the only similarity between this research 
and the aforementioned one [6] was the significantly higher 
consequence domain scores in patients with good quality INR 
control vis-à-vis those with poor quality INR control. Apart from 
that, patients with shorter TTRs had higher scores in the 
identity domain, thereby denoting a more negative effect of the 
illness on their lives. 
 
IP interacts with several factors like adherence to medications 
and lifestyle modifications. For instance, improved treatment 
control had a positive impact on medication adherence in 
hypertensive patients [27]. Apparently, good medication 
adherence in diabetic patients has resulted in better outcomes 
and personal control scores than their poorly compliant 
counterparts [28]. In this study, it was likely that the long-term 
maintenance of self-management in terms of diet control [16] 
and medication adherence [21] has helped the participants to 
achieve good quality INR control, which in turn produced better 
outcomes and personal control scores.  
 
With the assumption that IP was a better indicator of long-term 
anticoagulation control (based on the poorer IP in patients with 
lower TTRs), IP-related interventions should be held during 
patients’ encounters. Since educational interventions might not 
improve the IP [26], different approaches – like exploring issues 
and providing solutions from the IP’s point of view – might be 
better mechanisms for patients to adapt to their illnesses [28]. 
 
Strength and limitations 
This was the first study that investigated the relationships 
between TTR and INR with the newly developed MALMAS 
questionnaire in patients prescribed with warfarin. Current 
finding has also provided preliminary evidence that current INR 
readings was associated with MALMAS scores. However, this 
study was not without limitations. The sample size was rather 
small and inadequately powered due to the small numbers of 
patients diagnosed with heart-related conditions within this 
locality that required them to receive warfarin treatment. 
 
CONCLUSION 
To improve the quality of INR therapy in patients receiving 
warfarin, a multifaceted approach which addresses essential 
factors like medication adherence, social support, and patients’ 
perceived severity of their illnesses has to be implemented. 
Ideally, warfarin adherence assessments should be performed 
during every follow-up session, along with periodical 
evaluations of illness perceptions. 
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Table 1. Participants’ characteristics 
Characteristics Population (N=58) 
Age (years) 63.5(16.3) 
Male gender (n,%) 28(48.3) 
Income (RM) 950(1950) 
Diagnosis (n,%)  
AF 41(70.7) 
Others 17(29.3) 
Duration on warfarin treatment (months) 41.5(80.0) 
Appointment length (days) 27(19) 
Daily dose (mg)a 2.5(1.2) 
TTR control  
>60% 26(44.8) 
<60% 32(55.2) 
Adherence (n,%)  
Adherent 51(87.9) 
Nonadherent 7(12.1) 
Illness perception  
Identity 3.5(5.3) 
Timeline 9.0(4.3) 
Personal control 3.0(1.0) 
Treatment control 2.5(2.0) 
Consequence 3.0(4.0) 
Illness concern 9.0(2.0) 
Illness coherence 3.0(3.0) 
Emotional response 4.0(5.3) 
Total illness perception scorea 35.1(8.1) 
Social support  
Spousal  20.0(9.0) 
Familya 23.7(3.6) 
Friends  20.0(5.0) 
Total social supporta 65.3(11.3) 
                            Data are shown as median (IQR) except where indicated 
                                           aData are shown as mean (SD) 
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Table 2. Factors influencing TTR 
 TTR>60% TTR <60% P 
Age (years) 68(18) 59(22) 0.013 
Income (RM) 1000(1300) 300(1310) 0.020 
Duration on warfarin 
treatment (months) 
68(105) 38(48) 0.149 
Appointment length 
(days) 
42(20) 24(6) 0.000 
Daily dose (mg)a 2.3(1.0) 2.7(1.2) 0.170 
Illness perception    
Identity 3.0(5.5) 4.5(4.0) 0.039 
Timeline 9.0(5.0) 9.0(2.8) 0.489 
Personal control 2.0(2.0) 3.0(2.0) 0.047 
Treatment control 2.5(2.0) 2.5(1.0) 0.406 
Consequence 1.5(3.0) 3.0(4.8) 0.016 
Illness concern 9.0(2.0) 8.0(1.8) 0.204 
Illness coherence 3.5(3.0) 2.5(3.0) 0.441 
Emotional response 3.0(6.0) 5.5(5.0) 0.106 
Total illness scorea 32.1(7.5) 37.5(8.0) 0.012 
Social support    
Spousal  21.0(9.0) 20.0(10.5) 0.893 
Familya 23.9(4.0) 23.5(3.1) 0.628 
Friends  20.5(7.3) 20.0(4.3) 0.682 
Total social supporta 65.6(12.2) 65.0(10.6) 0.828 
Adherence (n,%)b   0.116 
Adherent 25(96.2) 26(81.3)  
Non-adherent 1(3.8) 6(18.7)  
              Data are shown as median (IQR) except where indicated 
                     aData are shown as mean (SD) 
              bData reported using Fisher’s Exact test 
 
